Global Conjugate Vaccines Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028
The Conjugate Vaccines market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest study, due to COVID-19 pandemic, the global Conjugate Vaccines market size is estimated to be worth US$ 11890 million in 2021 and is forecast to a readjusted size of USD 16960 million by 2028 with a CAGR of 5.2% during review period. Children accounting for % of the Conjugate Vaccines global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Monovalent Conjugate Vaccines segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Conjugate Vaccines include Novartis, Neuron Biotech, Serum Institute of India, Pfizer, and Sanofi Pasteur, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Conjugate Vaccines market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Monovalent Conjugate Vaccines
Multivalent Conjugate Vaccines
Market segment by Application can be divided into
Children
Adults
The key market players for global Conjugate Vaccines market are listed below:
Novartis
Neuron Biotech
Serum Institute of India
Pfizer
Sanofi Pasteur
Bharat Biotech
Biological
GlaxoSmithKline
Merck
CSL
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Conjugate Vaccines product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Conjugate Vaccines, with price, sales, revenue and global market share of Conjugate Vaccines from 2019 to 2022.
Chapter 3, the Conjugate Vaccines competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Conjugate Vaccines breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Conjugate Vaccines market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Conjugate Vaccines.
Chapter 13, 14, and 15, to describe Conjugate Vaccines sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Frequently Asked Questions
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
- By Type
- By Application
- By Region
- By Country
- By Manufacturer
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Conjugate Vaccines Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Conjugate Vaccines Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Monovalent Conjugate Vaccines
1.2.3 Multivalent Conjugate Vaccines
1.3 Market Analysis by Application
1.3.1 Overview: Global Conjugate Vaccines Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Children
1.3.3 Adults
1.4 Global Conjugate Vaccines Market Size & Forecast
1.4.1 Global Conjugate Vaccines Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Conjugate Vaccines Sales in Volume (2017-2028)
1.4.3 Global Conjugate Vaccines Price (2017-2028)
1.5 Global Conjugate Vaccines Production Capacity Analysis
1.5.1 Global Conjugate Vaccines Total Production Capacity (2017-2028)
1.5.2 Global Conjugate Vaccines Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Conjugate Vaccines Market Drivers
1.6.2 Conjugate Vaccines Market Restraints
1.6.3 Conjugate Vaccines Trends Analysis
2 Manufacturers Profiles
2.1 Novartis
2.1.1 Novartis Details
2.1.2 Novartis Major Business
2.1.3 Novartis Conjugate Vaccines Product and Services
2.1.4 Novartis Conjugate Vaccines Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Neuron Biotech
2.2.1 Neuron Biotech Details
2.2.2 Neuron Biotech Major Business
2.2.3 Neuron Biotech Conjugate Vaccines Product and Services
2.2.4 Neuron Biotech Conjugate Vaccines Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Serum Institute of India
2.3.1 Serum Institute of India Details
2.3.2 Serum Institute of India Major Business
2.3.3 Serum Institute of India Conjugate Vaccines Product and Services
2.3.4 Serum Institute of India Conjugate Vaccines Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Pfizer
2.4.1 Pfizer Details
2.4.2 Pfizer Major Business
2.4.3 Pfizer Conjugate Vaccines Product and Services
2.4.4 Pfizer Conjugate Vaccines Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Sanofi Pasteur
2.5.1 Sanofi Pasteur Details
2.5.2 Sanofi Pasteur Major Business
2.5.3 Sanofi Pasteur Conjugate Vaccines Product and Services
2.5.4 Sanofi Pasteur Conjugate Vaccines Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Bharat Biotech
2.6.1 Bharat Biotech Details
2.6.2 Bharat Biotech Major Business
2.6.3 Bharat Biotech Conjugate Vaccines Product and Services
2.6.4 Bharat Biotech Conjugate Vaccines Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Biological
2.7.1 Biological Details
2.7.2 Biological Major Business
2.7.3 Biological Conjugate Vaccines Product and Services
2.7.4 Biological Conjugate Vaccines Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 GlaxoSmithKline
2.8.1 GlaxoSmithKline Details
2.8.2 GlaxoSmithKline Major Business
2.8.3 GlaxoSmithKline Conjugate Vaccines Product and Services
2.8.4 GlaxoSmithKline Conjugate Vaccines Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 Merck
2.9.1 Merck Details
2.9.2 Merck Major Business
2.9.3 Merck Conjugate Vaccines Product and Services
2.9.4 Merck Conjugate Vaccines Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 CSL
2.10.1 CSL Details
2.10.2 CSL Major Business
2.10.3 CSL Conjugate Vaccines Product and Services
2.10.4 CSL Conjugate Vaccines Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Conjugate Vaccines Breakdown Data by Manufacturer
3.1 Global Conjugate Vaccines Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Conjugate Vaccines Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Conjugate Vaccines
3.4 Market Concentration Rate
3.4.1 Top 3 Conjugate Vaccines Manufacturer Market Share in 2021
3.4.2 Top 6 Conjugate Vaccines Manufacturer Market Share in 2021
3.5 Global Conjugate Vaccines Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Conjugate Vaccines Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Conjugate Vaccines Market Size by Region
4.1.1 Global Conjugate Vaccines Sales in Volume by Region (2017-2028)
4.1.2 Global Conjugate Vaccines Revenue by Region (2017-2028)
4.2 North America Conjugate Vaccines Revenue (2017-2028)
4.3 Europe Conjugate Vaccines Revenue (2017-2028)
4.4 Asia-Pacific Conjugate Vaccines Revenue (2017-2028)
4.5 South America Conjugate Vaccines Revenue (2017-2028)
4.6 Middle East and Africa Conjugate Vaccines Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Conjugate Vaccines Sales in Volume by Type (2017-2028)
5.2 Global Conjugate Vaccines Revenue by Type (2017-2028)
5.3 Global Conjugate Vaccines Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Conjugate Vaccines Sales in Volume by Application (2017-2028)
6.2 Global Conjugate Vaccines Revenue by Application (2017-2028)
6.3 Global Conjugate Vaccines Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Conjugate Vaccines Sales by Type (2017-2028)
7.2 North America Conjugate Vaccines Sales by Application (2017-2028)
7.3 North America Conjugate Vaccines Market Size by Country
7.3.1 North America Conjugate Vaccines Sales in Volume by Country (2017-2028)
7.3.2 North America Conjugate Vaccines Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Conjugate Vaccines Sales by Type (2017-2028)
8.2 Europe Conjugate Vaccines Sales by Application (2017-2028)
8.3 Europe Conjugate Vaccines Market Size by Country
8.3.1 Europe Conjugate Vaccines Sales in Volume by Country (2017-2028)
8.3.2 Europe Conjugate Vaccines Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Conjugate Vaccines Sales by Type (2017-2028)
9.2 Asia-Pacific Conjugate Vaccines Sales by Application (2017-2028)
9.3 Asia-Pacific Conjugate Vaccines Market Size by Region
9.3.1 Asia-Pacific Conjugate Vaccines Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Conjugate Vaccines Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Conjugate Vaccines Sales by Type (2017-2028)
10.2 South America Conjugate Vaccines Sales by Application (2017-2028)
10.3 South America Conjugate Vaccines Market Size by Country
10.3.1 South America Conjugate Vaccines Sales in Volume by Country (2017-2028)
10.3.2 South America Conjugate Vaccines Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Conjugate Vaccines Sales by Type (2017-2028)
11.2 Middle East & Africa Conjugate Vaccines Sales by Application (2017-2028)
11.3 Middle East & Africa Conjugate Vaccines Market Size by Country
11.3.1 Middle East & Africa Conjugate Vaccines Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Conjugate Vaccines Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Conjugate Vaccines and Key Manufacturers
12.2 Manufacturing Costs Percentage of Conjugate Vaccines
12.3 Conjugate Vaccines Production Process
12.4 Conjugate Vaccines Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Conjugate Vaccines Typical Distributors
13.3 Conjugate Vaccines Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer
List of Tables
Table 1. Global Conjugate Vaccines Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Conjugate Vaccines Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Novartis Basic Information, Manufacturing Base and Competitors
Table 4. Novartis Major Business
Table 5. Novartis Conjugate Vaccines Product and Services
Table 6. Novartis Conjugate Vaccines Sales (K Doses), Price (USD/Doses), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Neuron Biotech Basic Information, Manufacturing Base and Competitors
Table 8. Neuron Biotech Major Business
Table 9. Neuron Biotech Conjugate Vaccines Product and Services
Table 10. Neuron Biotech Conjugate Vaccines Sales (K Doses), Price (USD/Doses), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. Serum Institute of India Basic Information, Manufacturing Base and Competitors
Table 12. Serum Institute of India Major Business
Table 13. Serum Institute of India Conjugate Vaccines Product and Services
Table 14. Serum Institute of India Conjugate Vaccines Sales (K Doses), Price (USD/Doses), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. Pfizer Basic Information, Manufacturing Base and Competitors
Table 16. Pfizer Major Business
Table 17. Pfizer Conjugate Vaccines Product and Services
Table 18. Pfizer Conjugate Vaccines Sales (K Doses), Price (USD/Doses), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. Sanofi Pasteur Basic Information, Manufacturing Base and Competitors
Table 20. Sanofi Pasteur Major Business
Table 21. Sanofi Pasteur Conjugate Vaccines Product and Services
Table 22. Sanofi Pasteur Conjugate Vaccines Sales (K Doses), Price (USD/Doses), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. Bharat Biotech Basic Information, Manufacturing Base and Competitors
Table 24. Bharat Biotech Major Business
Table 25. Bharat Biotech Conjugate Vaccines Product and Services
Table 26. Bharat Biotech Conjugate Vaccines Sales (K Doses), Price (USD/Doses), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. Biological Basic Information, Manufacturing Base and Competitors
Table 28. Biological Major Business
Table 29. Biological Conjugate Vaccines Product and Services
Table 30. Biological Conjugate Vaccines Sales (K Doses), Price (USD/Doses), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table 32. GlaxoSmithKline Major Business
Table 33. GlaxoSmithKline Conjugate Vaccines Product and Services
Table 34. GlaxoSmithKline Conjugate Vaccines Sales (K Doses), Price (USD/Doses), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 35. Merck Basic Information, Manufacturing Base and Competitors
Table 36. Merck Major Business
Table 37. Merck Conjugate Vaccines Product and Services
Table 38. Merck Conjugate Vaccines Sales (K Doses), Price (USD/Doses), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 39. CSL Basic Information, Manufacturing Base and Competitors
Table 40. CSL Major Business
Table 41. CSL Conjugate Vaccines Product and Services
Table 42. CSL Conjugate Vaccines Sales (K Doses), Price (USD/Doses), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 43. Global Conjugate Vaccines Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Doses)
Table 44. Global Conjugate Vaccines Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 45. Market Position of Manufacturers in Conjugate Vaccines, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 46. Global Conjugate Vaccines Production Capacity by Company, (K Doses): 2020 VS 2021
Table 47. Head Office and Conjugate Vaccines Production Site of Key Manufacturer
Table 48. Conjugate Vaccines New Entrant and Capacity Expansion Plans
Table 49. Conjugate Vaccines Mergers & Acquisitions in the Past Five Years
Table 50. Global Conjugate Vaccines Sales by Region (2017-2022) & (K Doses)
Table 51. Global Conjugate Vaccines Sales by Region (2023-2028) & (K Doses)
Table 52. Global Conjugate Vaccines Revenue by Region (2017-2022) & (USD Million)
Table 53. Global Conjugate Vaccines Revenue by Region (2023-2028) & (USD Million)
Table 54. Global Conjugate Vaccines Sales by Type (2017-2022) & (K Doses)
Table 55. Global Conjugate Vaccines Sales by Type (2023-2028) & (K Doses)
Table 56. Global Conjugate Vaccines Revenue by Type (2017-2022) & (USD Million)
Table 57. Global Conjugate Vaccines Revenue by Type (2023-2028) & (USD Million)
Table 58. Global Conjugate Vaccines Price by Type (2017-2022) & (USD/Doses)
Table 59. Global Conjugate Vaccines Price by Type (2023-2028) & (USD/Doses)
Table 60. Global Conjugate Vaccines Sales by Application (2017-2022) & (K Doses)
Table 61. Global Conjugate Vaccines Sales by Application (2023-2028) & (K Doses)
Table 62. Global Conjugate Vaccines Revenue by Application (2017-2022) & (USD Million)
Table 63. Global Conjugate Vaccines Revenue by Application (2023-2028) & (USD Million)
Table 64. Global Conjugate Vaccines Price by Application (2017-2022) & (USD/Doses)
Table 65. Global Conjugate Vaccines Price by Application (2023-2028) & (USD/Doses)
Table 66. North America Conjugate Vaccines Sales by Country (2017-2022) & (K Doses)
Table 67. North America Conjugate Vaccines Sales by Country (2023-2028) & (K Doses)
Table 68. North America Conjugate Vaccines Revenue by Country (2017-2022) & (USD Million)
Table 69. North America Conjugate Vaccines Revenue by Country (2023-2028) & (USD Million)
Table 70. North America Conjugate Vaccines Sales by Type (2017-2022) & (K Doses)
Table 71. North America Conjugate Vaccines Sales by Type (2023-2028) & (K Doses)
Table 72. North America Conjugate Vaccines Sales by Application (2017-2022) & (K Doses)
Table 73. North America Conjugate Vaccines Sales by Application (2023-2028) & (K Doses)
Table 74. Europe Conjugate Vaccines Sales by Country (2017-2022) & (K Doses)
Table 75. Europe Conjugate Vaccines Sales by Country (2023-2028) & (K Doses)
Table 76. Europe Conjugate Vaccines Revenue by Country (2017-2022) & (USD Million)
Table 77. Europe Conjugate Vaccines Revenue by Country (2023-2028) & (USD Million)
Table 78. Europe Conjugate Vaccines Sales by Type (2017-2022) & (K Doses)
Table 79. Europe Conjugate Vaccines Sales by Type (2023-2028) & (K Doses)
Table 80. Europe Conjugate Vaccines Sales by Application (2017-2022) & (K Doses)
Table 81. Europe Conjugate Vaccines Sales by Application (2023-2028) & (K Doses)
Table 82. Asia-Pacific Conjugate Vaccines Sales by Region (2017-2022) & (K Doses)
Table 83. Asia-Pacific Conjugate Vaccines Sales by Region (2023-2028) & (K Doses)
Table 84. Asia-Pacific Conjugate Vaccines Revenue by Region (2017-2022) & (USD Million)
Table 85. Asia-Pacific Conjugate Vaccines Revenue by Region (2023-2028) & (USD Million)
Table 86. Asia-Pacific Conjugate Vaccines Sales by Type (2017-2022) & (K Doses)
Table 87. Asia-Pacific Conjugate Vaccines Sales by Type (2023-2028) & (K Doses)
Table 88. Asia-Pacific Conjugate Vaccines Sales by Application (2017-2022) & (K Doses)
Table 89. Asia-Pacific Conjugate Vaccines Sales by Application (2023-2028) & (K Doses)
Table 90. South America Conjugate Vaccines Sales by Country (2017-2022) & (K Doses)
Table 91. South America Conjugate Vaccines Sales by Country (2023-2028) & (K Doses)
Table 92. South America Conjugate Vaccines Revenue by Country (2017-2022) & (USD Million)
Table 93. South America Conjugate Vaccines Revenue by Country (2023-2028) & (USD Million)
Table 94. South America Conjugate Vaccines Sales by Type (2017-2022) & (K Doses)
Table 95. South America Conjugate Vaccines Sales by Type (2023-2028) & (K Doses)
Table 96. South America Conjugate Vaccines Sales by Application (2017-2022) & (K Doses)
Table 97. South America Conjugate Vaccines Sales by Application (2023-2028) & (K Doses)
Table 98. Middle East & Africa Conjugate Vaccines Sales by Region (2017-2022) & (K Doses)
Table 99. Middle East & Africa Conjugate Vaccines Sales by Region (2023-2028) & (K Doses)
Table 100. Middle East & Africa Conjugate Vaccines Revenue by Region (2017-2022) & (USD Million)
Table 101. Middle East & Africa Conjugate Vaccines Revenue by Region (2023-2028) & (USD Million)
Table 102. Middle East & Africa Conjugate Vaccines Sales by Type (2017-2022) & (K Doses)
Table 103. Middle East & Africa Conjugate Vaccines Sales by Type (2023-2028) & (K Doses)
Table 104. Middle East & Africa Conjugate Vaccines Sales by Application (2017-2022) & (K Doses)
Table 105. Middle East & Africa Conjugate Vaccines Sales by Application (2023-2028) & (K Doses)
Table 106. Conjugate Vaccines Raw Material
Table 107. Key Manufacturers of Conjugate Vaccines Raw Materials
Table 108. Direct Channel Pros & Cons
Table 109. Indirect Channel Pros & Cons
Table 110. Conjugate Vaccines Typical Distributors
Table 111. Conjugate Vaccines Typical Customers
List of Figures
Figure 1. Conjugate Vaccines Picture
Figure 2. Global Conjugate Vaccines Revenue Market Share by Type in 2021
Figure 3. Monovalent Conjugate Vaccines
Figure 4. Multivalent Conjugate Vaccines
Figure 5. Global Conjugate Vaccines Revenue Market Share by Application in 2021
Figure 6. Children
Figure 7. Adults
Figure 8. Global Conjugate Vaccines Revenue, (USD Million) & (K Doses): 2017 & 2021 & 2028
Figure 9. Global Conjugate Vaccines Revenue and Forecast (2017-2028) & (USD Million)
Figure 10. Global Conjugate Vaccines Sales (2017-2028) & (K Doses)
Figure 11. Global Conjugate Vaccines Price (2017-2028) & (USD/Doses)
Figure 12. Global Conjugate Vaccines Production Capacity (2017-2028) & (K Doses)
Figure 13. Global Conjugate Vaccines Production Capacity by Geographic Region: 2022 VS 2028
Figure 14. Conjugate Vaccines Market Drivers
Figure 15. Conjugate Vaccines Market Restraints
Figure 16. Conjugate Vaccines Market Trends
Figure 17. Global Conjugate Vaccines Sales Market Share by Manufacturer in 2021
Figure 18. Global Conjugate Vaccines Revenue Market Share by Manufacturer in 2021
Figure 19. Conjugate Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 20. Top 3 Conjugate Vaccines Manufacturer (Revenue) Market Share in 2021
Figure 21. Top 6 Conjugate Vaccines Manufacturer (Revenue) Market Share in 2021
Figure 22. Global Conjugate Vaccines Sales Market Share by Region (2017-2028)
Figure 23. Global Conjugate Vaccines Revenue Market Share by Region (2017-2028)
Figure 24. North America Conjugate Vaccines Revenue (2017-2028) & (USD Million)
Figure 25. Europe Conjugate Vaccines Revenue (2017-2028) & (USD Million)
Figure 26. Asia-Pacific Conjugate Vaccines Revenue (2017-2028) & (USD Million)
Figure 27. South America Conjugate Vaccines Revenue (2017-2028) & (USD Million)
Figure 28. Middle East & Africa Conjugate Vaccines Revenue (2017-2028) & (USD Million)
Figure 29. Global Conjugate Vaccines Sales Market Share by Type (2017-2028)
Figure 30. Global Conjugate Vaccines Revenue Market Share by Type (2017-2028)
Figure 31. Global Conjugate Vaccines Price by Type (2017-2028) & (USD/Doses)
Figure 32. Global Conjugate Vaccines Sales Market Share by Application (2017-2028)
Figure 33. Global Conjugate Vaccines Revenue Market Share by Application (2017-2028)
Figure 34. Global Conjugate Vaccines Price by Application (2017-2028) & (USD/Doses)
Figure 35. North America Conjugate Vaccines Sales Market Share by Type (2017-2028)
Figure 36. North America Conjugate Vaccines Sales Market Share by Application (2017-2028)
Figure 37. North America Conjugate Vaccines Sales Market Share by Country (2017-2028)
Figure 38. North America Conjugate Vaccines Revenue Market Share by Country (2017-2028)
Figure 39. United States Conjugate Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 40. Canada Conjugate Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 41. Mexico Conjugate Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 42. Europe Conjugate Vaccines Sales Market Share by Type (2017-2028)
Figure 43. Europe Conjugate Vaccines Sales Market Share by Application (2017-2028)
Figure 44. Europe Conjugate Vaccines Sales Market Share by Country (2017-2028)
Figure 45. Europe Conjugate Vaccines Revenue Market Share by Country (2017-2028)
Figure 46. Germany Conjugate Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. France Conjugate Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. United Kingdom Conjugate Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. Russia Conjugate Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. Italy Conjugate Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Asia-Pacific Conjugate Vaccines Sales Market Share by Region (2017-2028)
Figure 52. Asia-Pacific Conjugate Vaccines Sales Market Share by Application (2017-2028)
Figure 53. Asia-Pacific Conjugate Vaccines Sales Market Share by Region (2017-2028)
Figure 54. Asia-Pacific Conjugate Vaccines Revenue Market Share by Region (2017-2028)
Figure 55. China Conjugate Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Japan Conjugate Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Korea Conjugate Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. India Conjugate Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Southeast Asia Conjugate Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Australia Conjugate Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. South America Conjugate Vaccines Sales Market Share by Type (2017-2028)
Figure 62. South America Conjugate Vaccines Sales Market Share by Application (2017-2028)
Figure 63. South America Conjugate Vaccines Sales Market Share by Country (2017-2028)
Figure 64. South America Conjugate Vaccines Revenue Market Share by Country (2017-2028)
Figure 65. Brazil Conjugate Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. Argentina Conjugate Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. Middle East & Africa Conjugate Vaccines Sales Market Share by Type (2017-2028)
Figure 68. Middle East & Africa Conjugate Vaccines Sales Market Share by Application (2017-2028)
Figure 69. Middle East & Africa Conjugate Vaccines Sales Market Share by Region (2017-2028)
Figure 70. Middle East & Africa Conjugate Vaccines Revenue Market Share by Region (2017-2028)
Figure 71. Turkey Conjugate Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. Egypt Conjugate Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. Saudi Arabia Conjugate Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. South Africa Conjugate Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Manufacturing Cost Structure Analysis of Conjugate Vaccines in 2021
Figure 76. Manufacturing Process Analysis of Conjugate Vaccines
Figure 77. Conjugate Vaccines Industrial Chain
Figure 78. Sales Channel: Direct Channel vs Indirect Channel
Figure 79. Methodology
Figure 80. Research Process and Data Source
